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The human M5 muscarinic acetylcholine receptor (mAChR) has re-
cently emerged as an exciting therapeutic target for treating a
range of disorders, including drug addiction. However, a lack of
structural information for this receptor subtype has limited further
drug development and validation. Here we report a high-resolution
crystal structure of the human M5 mAChR bound to the clinically
used inverse agonist, tiotropium. This structure allowed for a com-
parison across all 5 mAChR family members that revealed important
differences in both orthosteric and allosteric sites that could inform
the rational design of selective ligands. These structural studies,
together with chimeric swaps between the extracellular regions of
the M2 and M5 mAChRs, provided structural insight into kinetic
selectivity, where ligands show differential residency times be-
tween related family members. Collectively, our study provides im-
portant insights into the nature of orthosteric and allosteric ligand
interaction across the mAChR family that could be exploited for the
design of selective drugs.
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The muscarinic acetylcholine (ACh) receptors (mAChRs) areclass A G protein-coupled receptors (GPCRs) that together
with the nicotinic acetylcholine receptors facilitate the actions of
the neurotransmitter, ACh, throughout the body. The mAChR
family comprises 5 subtypes in which M1, M3, and M5 are pref-
erentially coupled to the Gq/11 protein-mediated signaling path-
ways, and M2 and M4 show preference for Gi/o protein-dependent
signaling. Localization studies have revealed that the mAChR
subtypes are differentially distributed, with M1, M4, and M5
mAChRs found predominantly in the central nervous system
(CNS), where they are essential for normal neuronal function,
while M2 and M3 mAChRs are expressed more widely, including
in the periphery, where they are involved in cardiovascular as well
as gut motility and secretory processes (1).
Given the involvement of mAChRs in such a wide range of
fundamental physiological processes, they have long been valued
as targets for novel therapeutics, in particular the central M1 and
M4 mAChRs, which have garnered attention due to their in-
volvement in cognition and memory (2). In contrast, relatively
less is known about the M5 mAChR subtype, which represents
less than 2% of the total CNS mAChR population (3, 4). Despite
its low level of expression, this receptor plays a vital role in the
mesolimbic reward pathway due to its presence on dopaminergic
neurons of the ventral tegmental area (5–8). Additionally, there
is a large population of nonneuronal M5 mAChRs located within
the endothelium of the cerebral vasculature, suggesting that the
receptor may modulate cerebral vasodilatory processes (9, 10).
These observations correlate well with phenotypic data from M5
mAChR knockout mice where the cerebral vasculature is con-
stitutively constricted, resulting in decreased cerebral blood flow
(11, 12). Additionally, M5 mAChR knockout mice exhibited at-
tenuated reward-seeking behavior to drugs of addiction, such as
cocaine and morphine, in self-administration and conditioned
place-preference experiments (13–15). Moreover, in recent studies
involving rats (16–18), ethanol-seeking behavior and oxycodone
self-administration were attenuated by the selective M5 mAChR
negative allosteric modulator (NAM) ML375 (19). From these
studies, the M5 mAChR has emerged as a potential target for the
treatment of drug addiction.
Despite such promising data, further study of the M5 mAChR
has been hindered by a lack of selective small-molecule tool
compounds. Designing conventional small-molecule ligands that
target the orthosteric ACh-binding site of individual mAChR sub-
types has been challenging due to the highly conserved sequence
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homology of the mAChR orthosteric site residues (1) and in part
due to a lack of detailed structural information for all 5 receptor
subtypes. While structures of the M1 to M4 mAChRs have been
previously determined, there are no available structures for the M5
mAChR. Therefore, to provide a complete structural comparison
of all 5 family members, we determined a high-resolution crystal
structure of the M5 mAChR, which revealed differences in the
extracellular loop (ECL) regions that could mediate orthosteric and
allosteric ligand selectivity. Based on these differences and the fact
that some medicines are now known to have different binding rates
between mAChR subtypes that can result in clinically relevant
“kinetic” selectivity, we also made chimeric swaps of the ECL re-
gions between the M2 and M5 mAChRs to investigate the role of
these regions in mediating this important mode of drug selectivity.
Results
Crystallization and Determination of the M5 mAChR Structure. To
determine the M5 mAChR structure, we designed a construct in
which residues 225 to 430 of intracellular loop 3 were removed
and replaced with a T4 lysozyme (T4L) fusion protein. Addi-
tionally, to promote crystallization, the first 20 N-terminal amino
acids were cleaved by a tobacco etch virus protease site engi-
neered into the receptor (SI Appendix, Fig. S1). The inverse
agonist, tiotropium, was used to stabilize the inactive state as it
has a slow dissociation rate at the M5 mAChR (20) and was also
used in the determination of the M1, M3, and M4 mAChR
structures (21, 22). The M5-T4L•tiotropium complex was crys-
tallized in lipidic cubic phase (LCP), and crystals were obtained
within 1 to 2 d; however, despite many rounds of optimization,
diffraction was limited to 7 Å. To improve the resolution, we built
upon a study from Kajiwara et al. (23) that predicted that mu-
tation of the amino acid at position 3.39 [numbered according to
Ballesteros-Weinstein (24)] to Arg would create a thermo-
stabilized receptor by promoting an ionic bond between this
residue and the highly conserved D2.50 residue. Recently, the
same S3.39R mutation was applied to the M2 mAChR, resulting in
a series of higher resolution structures (25). Although introduc-
tion of the S1173.39R mutation resulted in a construct that binds
the antagonists N-methyl scopolamine (NMS) or tiotropium with
a slightly reduced affinity relative to the wild-type (WT) M5
mAChR, the effect of the mutation on reducing ACh affinity was
substantially more pronounced (SI Appendix, Fig. S1), consistent
with the ability of the construct to favor an inactive over an active
state. Similar differential effects on antagonist versus agonist af-
finity were previously observed for S3.39R at the M2 mAChR (25).
Notably, introduction of the S1173.39R mutation increased our M5
mAChR yields during purification and resulted in crystals that
diffracted to a resolution of 3.4 Å. Data were collected from ∼130
crystals, and the structure was determined by molecular re-
placement using the M3 structure [Protein Data Bank (PDB) ID
4U15] and an ensemble of T4L structures as templates (Fig. 1A
and SI Appendix, Table S1).
To investigate the nature of NAM binding to the M5 mAChR,
we attempted to obtain cocrystal structures. Given that the bis-
ammonium alkane-type ligands tend to have higher affinities for
the M5 mAChR than the prototypical modulator, gallamine (26),
we tried to obtain a ternary complex structure of the M5 mAChR
with tiotropium and several bis-ammonium alkane ligands (Fig.
1B). We initially used the modulator 4B-C7/3-phth, which resulted
in crystals that grew to a much larger size and diffracted to a
resolution of 2.55 Å (Fig. 1 and SI Appendix, Table S2 and Fig.
S2). Based on previous data (27), we predicted that 4B-C7/3-phth
would bind in the extracellular vestibule (ECV). While there were
regions of strong electron density present in the ECV, we could
not unambiguously model 4B-C7/3-phth into the density as a
molecule of the precipitant, polyethylene glycol 400 (PEG400),
also likely binds in this site (22, 28) and may explain why
researchers have had difficulty in obtaining co-NAM–bound
structures for the mAChRs.
Subsequently, we designed 2 bis-ammonium alkane analogs
using the higher affinity 4P-C7/3-phth scaffold (27) to try to im-
prove modulator affinity (Fig. 1B) and detectability by X-rays. The
first modification added 2 bromine (Br) atoms (4P-C7/3-bromo-
phth) to increase the size of the pthalamide groups (29), and the
second modification rigidified the flexible 7-carbon linker with an
aromatic hydrocarbon (4P-aryl-C7/3-bromo-phth). When tested in
functional inositol phosphate (IP1) assays and [
3H]NMS compe-
tition radioligand binding, both ligands had a similar affinity in
relation to the parent compound (4P-C7/3-phth) (SI Appendix,
Figs. S3A and S4 and Table S3). Like 4B-C7/3-phth, the addition
of either 4P-C7/3-bromo-phth or 4P-aryl-C7/3-bromo-phth to pu-
rified M5 mAChR and reconstitution into LCP yielded crystals
that diffracted to a higher resolution (SI Appendix, Table S1). A
full dataset for the 4P-aryl-C7/3-bromo-phth was collected at a
wavelength of 0.92 Å to maximize the anomalous Br signal in a
single wavelength anomalous diffraction experiment; however, no
such signal was detected, suggesting that 4P-aryl-C7/3-bromo-phth
was not present in the structure. Since the structure was solved by
merging a large number of datasets, there is a possibility that the
Br signal for the NAM would be averaged out if NAM occupancy
is low. However, inspection of different datasets did not indicate
that this was the case.
As an alternate strategy, we attempted to determine a cocrystal
structure with the structurally diverse M5 mAChR-selective NAM,
ML375 (19). In comparison to the bis-ammonium ligands, the
addition of ML375 resulted in a slightly lower resolution structure
(2.7 Å, SI Appendix, Table S1), and, as was the case with the bis-
ammonium NAMs, we were not able to assign ML375 any electron
density. Comparison of all M5 mAChR structures showed that they
were nearly identical, with root mean square deviation values of
0.09 to 0.22 Å. The higher-resolution 2.55 Å M5•tiotropium (4B-
C7/3-phth) structure was used for further comparison, as this was
the best-resolved and modeled structure (SI Appendix, Fig. S5).
Family-Wide Comparison of All mAChR Subtypes. The solution of the
M5 mAChR structure allows for a complete subtype-wide com-
parison of this important GPCR family. The structure of the M5
mAChR is similar to the previously determined structures of the
M1 to M4 mAChR subtypes (21, 22, 30) with a root mean squared
deviation of 0.5 to 0.8 Å (Fig. 2A) for the 7-transmembrane do-
main across all subtypes. The 5 mAChR subtypes are most similar
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Fig. 1. Structures of M5-T4L bound to tiotropium. (A) Overlay of 5 different
M5 mAChR structures determined in the presence of tiotropium and (B)
different allosteric modulators. The structure from 4B-C7/3-phth was the
most resolved of all of the datasets and is used in all further comparisons.
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in the orthosteric binding site, which is the most conserved region
of the receptor. The fact that our M5 mAChR structure was
obtained in complex with the same ligand (tiotropium) as the M1,
M3, and M4 mAChR structures allowed for a specific, detailed
comparison of residues lining this orthosteric binding site (Fig. 2 B
and C). This comparison demonstrated that the residues within
the orthosteric pocket are absolutely conserved between the re-
ceptors. Although there is no tiotropium-bound M2 mAChR struc-
ture, there are now 6 different inactive state M2 mAChR structures,
which include structures bound with the nonselective ligands 3-
quinuclidinyl benzilate (QNB) and NMS and the M2 mAChR
selective ligand AF-DX384 (25). The 2.3-Å M2•NMS structure is
most similar to the tiotropium-bound mAChR structures, al-
though residues Y3.33 and Y7.39 of the “tyrosine lid” (Y3.33, Y6.51,
and Y7.39) are positioned in a distinct conformation in comparison
to the tiotropium-bound structures. These differences in the ty-
rosine lid positions are more pronounced in the M2•AF-DX384
structures, allowing the accommodation of this bulkier ligand into
the orthosteric binding pocket (Fig. 2 B and C).
Subtle yet notable differences between the mAChR subtypes
are observed for ECL2 and ECL3, corresponding to regions that
are the least conserved across the receptors (Fig. 2D). At ECL2
there is a 1.8-Å difference across all 5 subtypes beginning at the
first nonconserved residue of ECL2. As ECL2 progresses toward
TM5, a conserved 310 helix motif moves inward by 2.8 Å in the
M5 mAChR when compared to the M1 structure. Similarly, the
conserved ECL3 disulphide bond is displaced inward by 3.1 Å for
the M3 and M5 mAChRs (Fig. 2D), relative to the other sub-
types. These observed differences in the positions of ECL2 and
ECL3, along with differences in amino acid composition, con-
tribute to a more constricted entrance to the orthosteric binding
site at the M5 (and M3) versus the M2 mAChR (Fig. 2E). Fur-
thermore, this contraction of the entrance in the antagonist-
bound structures may contribute to the slower dissociation rate
of orthosteric ligands from the M5 and M3 mAChRs, in com-
parison to other subtypes like the M2 mAChR. For example,
despite having similar equilibrium-binding affinities, [3H]NMS
dissociates 18-fold more slowly at the M5 than at the M2 mAChR
with half-lives of dissociation of 100 ± 11.6 and 5.7 ± 1.2 min,
respectively (Fig. 2 F and G).
Structural Differences between the ECVs of the M2 and M5 mAChRs.
An alternative strategy to generating selective ligands is to target
nonconserved allosteric sites (31). This has been extensively ex-
plored for the mAChR family in which a palette of both positive
and negative allosteric modulators has been identified (32, 33).
Structural and mutagenesis studies have established that many of
these ligands bind to a “common” allosteric site that is located
above the orthosteric site and within an ECV (Fig. 3 and SI Ap-
pendix, Fig. S6) (34). In fact, the M5 mAChR has often served as a
model system for early research into understanding the binding
mode and mechanism of selectivity for prototypical modulators,
such as the bis-ammonium alkane ligands (Fig. 1B), that have
higher sensitivity for modulating the M2 mAChR and lower sen-
sitivity for the M5 mAChR (26, 35–38). These studies identified
nonconserved residues in ECL2 (P179−4, E182−1, and Q184+1;
superscript indicates the position of ECL2 residues relative to the
conserved Cys in ECL2) and TM7 (V4747.32 and H4847.36) as
residues that can account for M2/M5 subtype selectivity. Com-
parison of the ECV between the M2 and M5 mAChRs confirms
differences in the orientations and positions of these residues that
could mediate the selectivity. Namely, P179−4 in ECL2 restricts
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Fig. 2. Structural comparison of M1 to M5 mAChRs. (A) The overall view of the M1 to M5 mAChR structures aligned with the M5 mAChR and shown as cartoons.
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Values are significantly different (P value < 0.0001, 2-way ANOVA). Detailed statistical analysis is shown in SI Appendix, Table S5.
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the position of E182−1, forcing the residue into the ECV near
Q184+1. Residue Q184+1, which is a F/Y residue for the M1 to M4
mAChRs subtypes, is a key residue for the activity of many allo-
steric modulators. Other major differences between the M2/M5
ECVs are in the positions of nonconserved residues lining the top
of TM6 starting from S4656.58 across ECL3 and down to residue
H4787.36 in TM7. At the M5 mAChR, these residues are bulkier
and point more inwardly, constricting the overall size of the ECV
(Fig. 3).
Role of the M5 and M2 mAChR ECL Regions in Orthosteric and
Allosteric Ligand Binding. The effect of ECL regions on ortho-
steric ligand access and egress has significant biological and clinical
relevance (39). Therefore, to investigate the role of the ECLs in
modulating the slower dissociation kinetics of the M5 mAChR in
comparison with the M2 mAChR, we designed full ECL1, ECL2,
and/or ECL3 chimeric swaps between the 2 subtypes (Fig. 4 and SI
Appendix, Fig. S7). The ECL chimeras had similar levels of ex-
pression and binding of [3H]NMS to WT receptors (SI Appendix,
Table S4). As previously noted, the M2 mAChR has a shorter half-
life for [3H]NMS dissociation in comparison with the M5 mAChR
(Fig. 2F). Incorporation of the M2 ECL1 or ECL3 into the M5
mAChR increased [3H]NMS dissociation, while the reciprocal
chimeric swap decreased [3H]NMS dissociation at the M2 mAChR.
Unexpectedly, it was the ECL1 swaps that had the largest effect on
[3H]NMS dissociation between the 2 subtypes, particularly at the
M5 mAChR (Fig. 4 and SI Appendix, Table S5). A possible
structural explanation for this observation could be that R95ECL1,
which is a conserved Tyr residue at the M1 to M4 subtypes, is
capable of forming an ionic bond with either the M5 ECL2 residue
D181−2 or, in the case of the M2 ECL1 chimera, residue D173
−3
(Fig. 3 and SI Appendix, Fig. S6). Such an interaction could tether
ECL1 and ECL2, limiting their overall dynamics and thus reduce
rates of orthosteric ligand dissociation. It is important to note that
R95ECL1 is involved in an ionic interaction mediated through the
crystal lattice with a neighboring T4L molecule (SI Appendix, Fig.
S2D–F), and as a result it does not directly interact with D181−2 in
the M5 mAChR structure although it is well positioned to do so.
A hallmark feature of an allosteric ligand that modulates
orthosteric ligand affinity is the ability to either increase or de-
crease the rate of dissociation of an orthosteric ligand. To examine
the effect of allosteric modulators on NMS dissociation across the
M5 and M2 ECL chimeras, we used the bis-ammonium alkane
ligand 4P-C7/3-phth, which had been previously studied at the M2
mAChR and had high affinity for the M5 mAChR (SI Appendix,
Table S3) or the M5 selective modulator ML375 (19, 27). In the
presence of ML375, [3H]NMS dissociation was reduced at the M5
mAChR and had no effect at the M2 mAChR, whereas the ad-
dition of 4P-C7/3-phth reduced radioligand dissociation at the M2
mAChR but not at the M5 mAChR (Fig. 4 and SI Appendix, Table
S5). The ECL1 and ECL3 chimeric swaps had little effect on the
activity of ML375 for either receptor subtype and slightly in-
creased the activity of 4P-C7/3-phth at the M5 mAChR. For the
ECL2 chimeras, there was no effect on activity of ML375. How-
ever, there was a loss of 4P-C7/3-phth activity at the M2 mAChR
and a corresponding gain of activity at the M5 mAChR. These
results are in line with previous studies and highlight the impor-
tance of residues in ECL2, particularly M2-Y177 and M5-E184, on
modulating the activity of bis-ammonium alkane ligands. Inter-
estingly, when all 3 ECLs were swapped, the resulting M2 and M5
chimeric constructs functioned more like their swapped receptor
counterpart. That is, for the M2–M5-all-ECL construct, 4P-C7/3-
phth had little effect, and although ML375 did not retard [3H]
NMS dissociation, it slightly increased the rate of [3H]NMS dis-
sociation, suggesting an allosteric mode of action (Fig. 4 and SI
Appendix, Table S5). Conversely, for the M5–M2-all-ECL con-
struct, 4P-C7/3-phth retarded radioligand dissociation, and, surpris-
ingly, ML375 had no effect. While none of the chimeric constructs
ever fully switched the basal dissociation rate of [3H]NMS or
ML375 activity to that observed for the corresponding WT con-
structs, the data nonetheless suggest that the ECL regions mod-
ulate the overall conformation of mAChRs and directly influence
the dissociation of ligands from the orthosteric site.
Discussion
Individual mAChR subtypes have long been pursued as drug
targets for a range of CNS disorders, and recent studies have
begun to validate the M5 mAChR as a target for the treatment of
drug addiction (4, 40). In this study, we have determined a high-
resolution crystal structure of the M5 mAChR, thus allowing a
subtype-wide comparison for any aminergic GPCR subfamily.
Introduction of the inactive state stabilizing mutation S1173.39R,
which was recently used to stabilize the M2 mAChR (25), was
crucial to obtaining well-diffracting crystals and suggests that this
mutation could be applied to aid the determination of inactive
state structures for other related GPCRs. We further improved
the resolution of the M5 mAChR structure by adding allosteric
modulators to the purified protein prior to crystallization. Despite
the consistent increase in resolution that each of the allosteric
modulators provided, we were not able to model any of the
modulators into electron density. From a pharmacological per-
spective, a lack of modulator binding is not surprising, as all of the
modulators tested in this study showed strong negative coopera-
tivity with tiotropium (SI Appendix, Fig. S3B). Nevertheless, it is
still paradoxical that the addition of an allosteric modulator can
clearly improve receptor crystallization and diffraction yet not be
visible in any resulting structures. This phenomenon has been
noted at other GPCRs, such as the M2 mAChR that was crystal-
lized in the presence of the modulator alcuronium and the CC
chemokine receptor 2A that was crystallized in the presence of the
modulator AZD-6942, but where neither modulator could be
observed in the resulting structures (25, 41).
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M5 mAChR, with residues in ECL2 numbered relative to the conserved cys-
teine in ECL2, which is shown as a yellow sphere. Sidechains for D4696.62 and
K470ECL3 are truncated to the β-carbon in the deposited model due to a lack
of sidechain density and are modeled here as the most probable rotamer.
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Comparison of all 5 mAChR structures further confirms the
well-conserved transmembrane core and orthosteric binding site
that has made the discovery of highly selective drugs for these
receptor subtypes incredibly challenging. The most apparent
structural differences between the mAChR subtypes are in the
ECL regions. Although these differences are generally quite sub-
tle, they are important because they open up the possibility for
designing selective molecules in a way that has not previously been
possible (SI Appendix, Fig. S6). For example, a recent crystal
structure of the M2 mAChR bound to the M2-selective antagonist
AF-DX384 revealed that selectivity is mediated by differential
interactions between the ligand and residues in ECL2, which lead
to an outward displacement in ECL2 and the top of TM5 (Fig. 2D)
(25). Likewise, by utilizing knowledge of a single amino acid dif-
ference in ECL2 between the M2 and M3 mAChRs, molecular
docking and structure-based design led to the discovery of an M3-
selective antagonist with 100-fold selectivity over the M2 mAChR
(42). These results are similar to the structure-based design of
biased ligands targeting the D2 dopamine receptor that were
designed by utilizing specific amino acid–ligand contacts in ECL2
and TM5 (43). Taken together, these findings indicate that the
differential targeting of ECL residues may be a path forward for
creating selective mAChR ligands. This is well supported by the
fact that many mAChR-selective allosteric modulators interact
with the ECL regions (27, 34) and suggests that designing ortho-
steric ligands linked to allosteric pharmacophores, known as
bitopic ligands, is a potential strategy for future structure-based
drug design.
Drug discovery has typically focused on optimizing ligand af-
finity and selectivity; however, it is now apparent that binding
kinetics can play a critical role in these events (39, 44–46). This is
illustrated in 2 ways with the drug tiotropium as a pertinent ex-
ample. First, tiotropium has slow rate of dissociation from the
M3 mAChR, which is a key feature of the drug that allows for a
once daily dosing for the treatment of chronic obstructive pul-
monary disease (47). Second, although tiotropium has the same
equilibrium-binding affinity for the M3 and M2 mAChRs, it ex-
hibits kinetic selectivity for the M3 over the M2 mAChR by
having substantially different rates of dissociation. This kinetic
selectivity over the M2 mAChR is postulated to be due to dif-
ferences in the electrostatics and dynamics of the ECL region
(47). The M5 mAChR is similar to the M3 mAChR with respect
to having slow rates of orthosteric ligand dissociation (20), and
data from our M2/M5 ECL chimeras support the idea of the ECL
regions underpinning kinetic selectivity as [3H]NMS dissociation
was switched between the M2 and M5 mAChRs (Fig. 4). Notably,
none of the combined ECL chimeras could ever fully switch the
dissociation kinetics between subtypes, suggesting that other
mechanisms are operative such as the global conformation of the
ECLs. Our results also highlight the importance of the ECL
regions on conferring sensitivity to allosteric modulators across
different subtypes. By swapping out the entire ECL region be-
tween the M2 and M5 mAChRs we were able to completely alter
the sensitivity of a modulator that is selective for the M2 versus
the M5 mAChR and vice versa. These results are in line with
previous studies using similar M2/M5 mAChR ECL chimeras
(35–38, 48) and, collectively with our findings, highlight the im-
portance of the ECL region for conferring subtype selectivity for
different types of mAChR ligands.
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Fig. 4. [3H]NMS binding dissociation kinetic studies of chimeric swaps between the ECLs of the M2 and M5 mAChRs. (A) Cartoons for the M2 and M5 ECL
chimeras used in this study. (B) [3H]NMS reassociation was prevented by the addition of 10 μM atropine, and radioligand dissociation was monitored in the
absence (Vehicle) or presence of 10 μM ML375 or 10 μM 4P-C7/3-phth. Data points represent the mean ± SEM of 3 or more independent experiments per-
formed in duplicate. (C) Comparison of the dissociation half-lives for [3H]NMS, showing both individual values and the mean ± SEM (log-scale). Full quan-
titative parameters derived from this experiment are listed in SI Appendix, Table S5, including a statistical analysis.
Vuckovic et al. PNAS | December 17, 2019 | vol. 116 | no. 51 | 26005
PH
A
RM
A
CO
LO
G
Y
In summary, our reported M5 mAChR crystal structure has
allowed for the comparison of all 5 mAChR subtypes and has
revealed that subtle differences in the ECL regions are a major
determinant in ligand selectivity, regardless of the ligand being
orthosteric or allosteric. As the M1, M4, and M5 mAChRs con-
tinue to emerge as exciting drug targets for the treatment of CNS
disorders, it will be important to understand both the structural
and the dynamic differences between all 5 mAChR subtypes in
order to aid design of safer and more effective small-molecule
therapeutics.
Materials and Methods
Detailed information on cloning, receptor purification, synthesis of the bis-
ammonium alkane ligands, and molecular pharmacology experiments is
provided in SI Appendix, Materials and Methods.
M5 Receptor Expression and Purification. M5-T4L with the S117
3.39R was pu-
rified similarly to previous methods (22).
Crystallization and Structure Determination. Purified M5-T4L S117
3.39R bound
to tiotropium was crystallized using LCP. For allosteric modulator cocrystal-
lization, the modulator was added to purified protein at a final concentra-
tion of 2.5 mM. The sample was incubated on ice for 3 h before it was mixed
into 10:1 (wt/wt) monoolein:cholesterol in 1:1.5 wt/wt protein:lipid ratio.
LCP crystallization was performed by spotting 25 to 30 nL of samples on a
siliconized 96-well glass plate overlaying the samples with 600 nL of pre-
cipitant solution using the Gryphon LCP (Art Robbins Instruments). Sealed
glass plates were incubated at 20 °C. Crystals appeared in the first 24 h and
grew to full size in the following 1 to 2 d. The best diffracting crystals grew
in 100 mM DL-Malic acid, pH 6.0; 220 to 280 mM ammonium tartrate dibasic;
and 37 to 41% PEG 400. For the data collection, whole drops were harvested
using mesh grid loops (Mitegen) and flash-frozen in liquid nitrogen.
X-ray diffraction data were collected at the SPring-8 (Japan) beamline
BL32XU (49) and the MX2 beamline at the Australian Synchrotron (50).
Diffraction data at SPring-8 was collected using the automatic data-
collection system ZOO (51). Diffraction data were processed using KAMO
(52) with XDS (53). The structure was solved using molecular replacement
with M3-mT4L (4U15) as a search model for the receptor and an ensemble of
T4L molecules for T4L. Structure refinement was performed with Phenix (54),
and the models were validated with MolProbity (55). Sidechains for residues
with no electron density (contoured at 1σ in a 2mjFoj − DjFcj map; SI Ap-
pendix, Fig. S5) past the β-carbon were truncated. Structure figures were
prepared using the program PyMol. Electrostatic and surface potential of M2
and M5 mAChR (+5kT/e in blue and −5kT/e in red) mapped on the surface
of the receptors calculated at pH 7.0 were calculated using PDB2PQR and
APBS (56).
Data Availability. Atomic coordinates and structure factors have been de-
posited in the Protein Data Bank, http://www.rcsb.org (PDB ID code 6OL9 for
M5-T4L). Detailed methods are provided in SI Appendix. Other materials and
data are available on request.
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